If approved, Spravato would mark the first monotherapy for treatment-resistant depression to hit the market in the United States.
Johnson & Johnson Submits Supplemental New Drug Application to FDA for Spravato as Monotherapy for Adults with Treatment-Resistant Depression
Leave a comment
